Abstract: An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: One embodiment of the present invention sets forth a technique for evaluating labeled data. The technique includes selecting, from a set of labels for a data sample, a subset of the labels representing non-outliers in a distribution of values in the set of labels. The technique also includes aggregating the subset of the labels into a benchmark for the data sample. The technique further includes generating, based on a comparison between the benchmark and an additional label, a benchmark score associated with the data sample, and generating a set of performance metrics for labeling the data sample based on the benchmark score.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: Disclosed herein, inter alia, are certain substituted thieno[3,2-b]pyrimidine compositions and methods for modulating Adenosine Receptors, for example, having the formula:

Abstract: A device and a method for simultaneously inspecting defects of a surface and a subsurface of an optical element are provided. Combined with laser-induced ultrasound and laser scattering inspection technologies, through generating acoustic sound waves on the surface and the subsurface of the optical element to be tested by lasers, a static light scattering effect of subsurface defects under modulation of the acoustic sound wave is observed and analyzed; through analyzing amplitude and phase changes of scattered light intensity and reflected light intensity, inspection for the defects of the surface and the subsurface of the optical element is realized. The present invention can be applied in quality inspection of precise optical elements, especially in finished product inspection of ultra-precise optical elements having strict requirements on the subsurface defects.

Abstract: The present invention relates to an alkyl chitosan-graphene oxide composite sponge and preparation method and application thereof. The alkyl chitosan-graphene oxide composite sponge provided by the present invention includes alkyl chitosan and graphene oxide absorbed on the alkyl chitosan, and the adsorbing capacity of the graphene oxide is 3-28 wt. %. In the present invention, alkyl chitosan is used as a matrix to combine graphene oxide and alkyl chitosan; the obtained composite sponge has excellent hemostatic performance and blood absorption capacity. Results of embodiments indicate that the in-vitro whole blood coagulation time is less than 58 s, the hemostasis time of a rabbit femoral artery hemorrhage model is less than 155 s, the hemorrhage mass is less than 5.4 g, and the hemostatic effect is superior to a pure alkyl chitosan sponge or graphene oxide powder when the composite sponge provided by the present invention is used for hemostasis.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: The present invention provides MDM2 inhibitor compounds of Formula I, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

Abstract: An 8-dihalomethyl berberine-type quaternary ammonium salt compound represented by general formula (I) or (II) and an application thereof in preparing a drug. The compound shows hydrophilicity and has antimicrobial, anti-inflammatory, anti-ulcerative colitis, and antitumor activities, while having no or low toxicity.

Abstract: A device and a method for simultaneously inspecting defects of a surface and a subsurface of an optical element are provided. Combined with laser-induced ultrasound and laser scattering inspection technologies, through generating acoustic sound waves on the surface and the subsurface of the optical element to be tested by lasers, a static light scattering effect of subsurface defects under modulation of the acoustic sound wave is observed and analyzed; through analyzing amplitude and phase changes of scattered light intensity and reflected light intensity, inspection for the defects of the surface and the subsurface of the optical element is realized. The present invention can be applied in quality inspection of precise optical elements, especially in finished product inspection of ultra-precise optical elements having strict requirements on the subsurface defects.

Abstract: Provided herein are myeloid cell leukemia 1 protein (Mcl-1) inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: An active power distribution network multi-time scale coordinated optimization scheduling method and storage medium are provided. The method includes the following steps: performing long-time scale optimization scheduling of an active power distribution network; performing short-time scale rolling optimization scheduling on the basis of MPC of the active power distribution network according to an optimization result of the long-time scale optimization scheduling of the active power distribution network. By using a model prediction control method, taking the long-time scale optimization scheduling result as a reference, and performing short-time scale rolling correction, the optimization scheduling of the active power distribution network is achieved, thereby reducing unfavorable influences of prediction precision of a distributed power supply and a low-voltage load on the optimization scheduling.

Abstract: The present invention relates to an alkyl chitosan-graphene oxide composite sponge and preparation method and application thereof. The alkyl chitosan-graphene oxide composite sponge provided by the present invention includes alkyl chitosan and graphene oxide absorbed on the alkyl chitosan, and the adsorbing capacity of the graphene oxide is 3-28 wt. %. In the present invention, alkyl chitosan is used as a matrix to combine graphene oxide and alkyl chitosan; the obtained composite sponge has excellent hemostatic performance and blood absorption capacity. Results of embodiments indicate that the in-vitro whole blood coagulation time is less than 58 s, the hemostasis time of a rabbit femoral artery hemorrhage model is less than 155 s, the hemorrhage mass is less than 5.4 g, and the hemostatic effect is superior to a pure alkyl chitosan sponge or graphene oxide powder when the composite sponge provided by the present invention is used for hemostasis.

Abstract: Disclosed herein, inter alia, are compositions and methods for modulating Adenosine Receptors.

Abstract: Provided herein are compounds that are useful intermediates that may used to synthesize myeloid cell leukemia 1 protein (Mcl-1) inhibitors. Also provided are Mcl-1 inhibitors, methods of their preparation, related pharmaceutical compositions, and methods of using the same. For example, provided herein are compounds of Formula I, and pharmaceutically acceptable salts thereof and pharmaceutical compositions containing the compounds. The compounds and compositions provided herein may be used, for example, in the treatment of diseases or conditions, such as cancer.

Abstract: An active power distribution network multi-time scale coordinated optimization scheduling method and storage medium are provided. The method includes the following steps: performing long-time scale optimization scheduling of an active power distribution network; performing short-time scale rolling optimization scheduling on the basis of MPC of the active power distribution network according to an optimization result of the long-time scale optimization scheduling of the active power distribution network. By using a model prediction control method, taking the long-time scale optimization scheduling result as a reference, and performing short-time scale rolling correction, the optimization scheduling of the active power distribution network is achieved, thereby reducing unfavorable influences of prediction precision of a distributed power supply and a low-voltage load on the optimization scheduling.

Abstract: The disclosure provides a method for preparing an electrolyte and an electrolyte replenishment system during an electrolytic process. The method includes the following steps: Step A: placing aluminum in a reactor, vacuumizing the reactor and feeding an inert gas, heating the reactor to 700-850 degrees centigrade, and adding one or more of potassium fluozirconate, potassium fluoborate, sodium hexafluorozirconate and sodium fluoroborate; and Step B: stirring the reactants for 4-6 hours and extracting the upper molten liquid to obtain an electrolyte replenishment system during an aluminum electrolysis process. The disclosure has the following beneficial effects: when used in the aluminum electrolysis industry, the electrolyte system provided herein can be directly used as an aluminum electrolyte or a replenishment system in an electrolyte without changing existing electrolysis technology to significantly reduce an electrolysis temperature during an aluminum electrolysis process.

Abstract: An optical fiber system including an optical fiber and an optical grating is provided. The optical fiber is configured to support M mode groups, where differences in effective refractive index between adjacent mode groups are substantially equal. The optical grating is optically coupled to the optical fiber, and has a period inversely proportional to the difference in effective refractive index between adjacent mode groups. The optical grating is configured to couple all adjacent mode groups in the optical fiber.